Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration

OPT-302 is a novel inhibitor of vascular endothelial growth factor (VEGF)-C and VEGF-D. A phase 1 trial assessed the safety of intravitreal OPT-302 as monotherapy or combined with ranibizumab (Lucentis; Genentech, South San Francisco, CA) in patients with neovascular age-related macular degeneration...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Ophthalmology retina 2020-03, Vol.4 (3), p.250-263
Hauptverfasser:	Dugel, Pravin U., Boyer, David S., Antoszyk, Andrew N., Steinle, Nathan C., Varenhorst, Michael P., Pearlman, Joel A., Gillies, Mark C., Finger, Robert P., Baldwin, Megan E., Leitch, Ian M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angiogenesis Inhibitors - administration & dosage Female Fluorescein Angiography - methods Follow-Up Studies Fundus Oculi Humans Macula Lutea - pathology Male Prospective Studies Tomography, Optical Coherence - methods Vascular Endothelial Growth Factor C - antagonists & inhibitors Vascular Endothelial Growth Factor D - antagonists & inhibitors Visual Acuity Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy Wet Macular Degeneration - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!